Companies Dominating the Pulmonary Embolism Drugs Landscape
- Janssen Global Services, LLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Abbott Laboratories
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- Daiichi Sankyo Company, Limited
- Siemens Healthcare GmbH
- Baxter International Inc.
Browse Key Market Insights with Data Illustration:
In the News
-
Janssen Pharmaceuticals, Inc. revealed the results from Phase 3 A DUE study. This Phase 3 study is to represent investigational single-tablet combination therapy.
-
Novartis AG got approval for Tafinlar (dabrafenib) + Mekinist (trametinib) from U.S. Food and Drug Administration (FDA). These medications are used to treat pediatric patients or people with brain cancer.
